Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities

Equity Bottom-Up

133 Views, 18 Jan 2022 09:00

EXECUTIVE SUMMARY

The small market space of peripheral T-cell lymphoma indication and the fierce market competition of other indications, products and candidates make the Company’s future commercialization performance uncertain.
The continuous large investment in R&D, high selling expenses, and declining R&D expending capitalization would further drag down profitability.
So, our view is that we are conservative about Chipscreen Biosciences’s outlook at the current stage.

detail (5-minute read)

WHAT’S TRENDING

Insights